Bellicum Logo.jpg
Bellicum Pharmaceuticals to Present at Jefferies 2019 Healthcare Conference
May 29, 2019 16:05 ET | Bellicum Pharmaceuticals, Inc.
HOUSTON, May 29, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
Bellicum Logo.jpg
Bellicum Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Operational Update
May 07, 2019 07:30 ET | Bellicum Pharmaceuticals, Inc.
Interim data for BPX-601 accepted for presentation at upcoming American Society of Clinical Oncology (ASCO) Annual Meeting Rivo-cel™ on-track for topline data readout from BP-004 pediatric trial in...
Bellicum Logo.jpg
Bellicum Pharmaceuticals to Participate in Jefferies 6th Annual IO Cell Therapy Summit
March 27, 2019 07:30 ET | Bellicum Pharmaceuticals, Inc.
HOUSTON, March 27, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
Official_Bellicum_Logo_RGB.jpg
Bellicum Announces Update on Clinical Hold of U.S. BPX-501 Studies
February 23, 2018 07:00 ET | Bellicum Pharmaceuticals, Inc.
HOUSTON, Feb. 23, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
Official_Bellicum_Logo_RGB.jpg
Bellicum Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate Update
August 08, 2017 16:05 ET | Bellicum Pharmaceuticals
Company updates BPX-501 program Enrollment progressing in early clinical trials of CAR T and TCR product candidates Company to host conference call and webcast on August 8 at 5:00 PM EDT HOUSTON,...
Official_Bellicum_Logo_RGB.jpg
Bellicum Announces Clinical Data on BPX-501 at Presidential Symposium of the 22nd Congress of the European Hematology Association
June 23, 2017 07:00 ET | Bellicum Pharmaceuticals
MADRID, Spain, June 23, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited...
Official_Bellicum_Logo_RGB.jpg
Bellicum Reports Clinical Results of BPX-501 in Pediatric Leukemias at the 22nd Congress of the European Hematology Association
June 23, 2017 07:00 ET | Bellicum Pharmaceuticals
MADRID, Spain, June 23, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited...
Official_Bellicum_Logo_RGB.jpg
Bellicum Pharmaceuticals Announces Closing of Public Offering
March 30, 2017 07:00 ET | Bellicum Pharmaceuticals
HOUSTON, March 30, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM) today announced the closing, on March 29, 2017, of its previously announced underwritten public offering of...
Official_Bellicum_Logo_RGB.jpg
Bellicum to Report Fourth Quarter and Full Year 2016 Financial Results and Host Conference Call and Webcast on March 13, 2017
March 06, 2017 07:00 ET | Bellicum Pharmaceuticals
HOUSTON, March 06, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...